🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Every day matters for blood cancer patients awaiting treatment. With the industry’s leading manufacturing turnaround time, we ensure rapid and reliable delivery of our CAR T-cell therapies, providing this potentially curative treatment to eligible patients, faster. #CellTherapy

As a senior distribution specialist at Kite, Mayra Escobar says the best part of her position is helping to contribute to a process that creates innovative treatments. #CellTherapy

A new docuseries from The Leukemia & Lymphoma Society offers a powerful look into the lives of people transformed by CAR T-cell therapy. We’re honored to sponsor this series, which not only highlights breakthrough science but also shares stories of resilience and hope.

We're looking forward to attending #AACR25 to discuss how we’re changing the way cancer is treated. Watch as Kite's Priti Hegde and Gilead Sciences’ Jackson Egen share how we leverage research across solid tumors and hematological malignancies to discover new treatment options.

For Gaurang Patel, a passion for patient care and scientific innovation helps advance manufacturing processes that make CAR T-cell therapy possible. In recognition of #AANHPI, we’re sharing his story in our Identity + Innovation spotlight.

#KiteNews: With Gilead Sciences, we’re announcing the presentation of transformative cancer research at #ASCO25 and #EHA2025. Read more: bit.ly/43gDjNP

We’ve been part of LABEST from the beginning. Los Angeles is our home, and we’re proud to help spotlight the innovation happening here to bring new treatments to patients. #LABEST2025

At Kite, we are singularly focused on achieving cures with cell therapy. On #WorldBloodCancerDay, we honor the patients, caregivers and care teams at the heart of this mission and reaffirm our commitment to changing the way cancer is treated.

From new discoveries to reclaiming hope, we’re driven by a collective goal – helping to bring more life to people living with cancer. Ahead of #ASCO25, watch Gilead Sciences and Kite leaders share what that means to them.

Today, we proudly join an international, multi-stakeholder coalition to launch #CARTVision, which aims to double the number of eligible patients treated with CAR T-cell therapy by 2030. CARTVision.com

We're joining Gilead Sciences at #ASCO25 to share how our singular focus on cell therapy is helping people living with cancer take back possibility.

#KiteNews: At #ASCO25, we shared new real-world data evaluating the safety and effectiveness of our CAR T-cell therapy in an outpatient setting for eligible patients with R/R large B-cell lymphoma. bit.ly/3Zb6pgk

We’re encouraged by early results of a Penn Medicine Phase 1 clinical study of CAR T-cell therapy in recurrent GBM in Nature Medicine. As the potential of CAR T expands beyond blood cancers, so does the hope for new options for patients. #ASCO25

We know that inclusion can drive innovation. As we mark the start of #PrideMonth, Gary Ryan, a leader in our Pride Alliance employee resource group, shares how creating space for authenticity can strengthen teams and spark bold ideas. #GileadLife

Our Global Head of Research Priti Hegde shares how Kite and Gilead Sciences are working together to tackle the next frontier in cell therapy: solid tumors. bit.ly/4jBiLFV #ASCO25

What would you tell your former self living with cancer? At #ASCO25, two advocates left powerful voicemails to their past selves – messages of reflection, resilience and the extraordinary fight to take back possibility in the face of cancer. Hear their inspiring stories.

Healthcare professionals, join us at #EHA2025 on Friday 13th June for our interactive symposium exploring CAR T-cell therapy in multiple myeloma. #CellTherapyTalks

Healthcare professionals, join us at #EHA2025 on Saturday 14th June for our interactive symposium exploring strategies to support clinicians in navigating the path to CAR T. #CellTherapyTalks

Healthcare professionals, join us at #18ICML on Tuesday 17th June to discuss advancements in CAR T-cell therapy for DLBCL. #CellTherapyTalks

We’re excited to share that our partner @Arcellx presented new data from the pivotal Phase 2 iMMagine-1 study in relapsed/refractory multiple myeloma at #EHA2025 today.